Our antibody development roots go deep
Novimmune has brought 7 monoclonal antibodies to clinical development stage, one of which, Emapalumab, has been approved by the FDA in 2018.
After the successful divestment of Emapalumab related activities, we now focus on our bispecific technology to build a pipeline of multispecific antibodies under the brand Light Chain Bioscience.
